Navigation Links
BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Date:10/19/2007

PRINCETON, N.J., Oct. 19 /PRNewswire/ -- BioWa, Inc. (BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants GSK non-exclusive rights to research and develop antibodies based on POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, and license fees. Other details of the agreement are not disclosed.

"GSK has long time remained a strong leader in the pharmaceutical industry for both innovation and marketing," said Dr. Masamichi Koike, President and CEO of BioWa. "With the breadth and depth of GSK research, we are pleased to partner with a company that has large capabilities in all sectors of research. This collaboration will fulfill BioWa's mission to create benefit of POTELLIGENT(R) Technology to patients as quickly as possible."

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanism of antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology significantly enhances ADCC activity of an antibody in vitro, thereby increasing the potential for improved activity in vivo.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd., Japan's pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of POTELLIGENT(R) Technology, which creates high ADCC monoclonal antibodies. Currently, BioWa is developing ADCC enhanced monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have POTELLIGENT(R) antibody products in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities. For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT(R) is the trademark of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... made significant investments in recruiting top industry experts, and expanding its LATAM network ... provides industry-leading tools for clients to manage their clinical trial projects. , The ...
(Date:4/27/2016)... ... 27, 2016 , ... Most consumers engage with biometrics technology ... secure access, voice recognition for hands-free communication, and facial recognition to help organize ... technology today. But if they asked Joey Pritikin, Vice President of Marketing ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding ... detection. , PathSensors deploys the CANARY® test platform for the detection of ...
(Date:4/27/2016)... 2016 ReportsnReports.com adds 2016 ... focus on US, EU, China ... the healthcare business intelligence collection of its growing ... report on the Flow Cytometry market spread across ... 282 tables and figures is now available at ...
Breaking Biology Technology:
(Date:3/17/2016)... , March 17, 2016 ABI Research, ... forecasts the global biometrics market will reach more ... 118% increase from 2015. Consumer electronics, particularly smartphones, ... fingerprint sensors anticipated to reach two billion shipments ... Dimitrios Pavlakis , Research Analyst at ABI ...
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
Breaking Biology News(10 mins):